MarginProbe use reduces re-excision surgeries while conserving tissue
Framingham, MA, December 7, 2011- Data from the MarginProbe system pivotal study were presented
today during the 2011 CTRC-AACR San Antonio Breast Cancer Symposium. The results were presented by Dr. Freya Schnabel, Director of Breast Surgery, NYU Langone Medical Center, New York University, New York, New York. In a 596 patient randomized study, adjunctive use of MarginProbe significantly improved surgical outcomes by improving surgeons’ ability to identify and immediately identify positive margins, reducing the number of patients requiring re-excision by 57%.“Second surgeries are difficult on the patient, both physically and emotionally,” said Dr. Schnabel. “On average, about 30% of patients will require more than one surgery to completely remove the cancer. In our study, we saw a similar rate in the control arm, but by using MarginProbe, we were able to cut that in half. This represents a substantial improvement in patient care and quality, as well as reducing costs. I am very excited to see the device available to surgeons in the US.”
“We are very pleased with the response of the surgeon community to these data. Every lumpectomy surgery has the need for improved ability to achieve cancer-free margins and we believe these data present substantial evidence supporting the approval and widespread adoption of the MarginProbe System”, said Dan Levangie, CEO of Dilon Devices.
About the MarginProbe System
The MarginProbe System enables real time detection of cancer at or near the surface of excised tissue specimens during surgery for breast cancer. The simple and immediate assessment of the surgical margins allows surgeons to immediately excise additional tissue, potentially saving a second procedure. The MarginProbe System is Dune’s first commercial product and is commercially available in Europe. The MarginProbe device is an investigational device in the U.S.
About Dilon Devices
Dilon Devices was founded in 2002 by Dr. Dan Hashimshony to realize the extraordinary medical potential of its proprietary tissue characterization technology. Offering
surgeons and radiologists the real time ability to identify cancerous tissues and react immediately, this technology holds the promise for a broad range of surgical and diagnostic
applications. Dilon Devices is a privately held company financed by Apax Partnerssince 2004. It has offices in the U.S., Israel, Germany and Switzerland. For more information, please visit www.dilon.com.